Genetics of Pheochromocytoma

Abstract

Pheochromocytoma (PHEO) and paraganglioma (PGL) are closely related neuroendocrine tumours of the chromaffin tissues of the sympathetic and parasympathetic nervous system. These rare tumours have a strong genetic component, with underlying germline and somatic mutations in one of 17 genes found in approximately 50%. Clinical presentations of PHEO/PGL vary based on the affected gene, and understanding these differences can help guide genetic testing, an important part of PHEO/PGL patient management. Despite the differences in presentation and gene function, all 17 genes may affect a single pathway. Particularly, recent proposals have focused on hypoxia‐inducible factors (HIFs) as key players in PHEO/PGL, due to the known pseudohypoxic environment found in these tumours and the central role played by HIFs in cellular processes. By linking the susceptibility genes to a central potential therapeutic target like HIF, new treatment methods could soon be introduced to improve the outcomes of PHEO/PGL patients.

Key Concepts:

  • Pheochromocytomas and paragangliomas have the strongest genetic component of any endocrine tumour; half or more are linked to germline and somatic mutations in 17 genes.

  • The clinical presentations associated with each gene vary, particularly with regard to tumour location, multiplicity, biochemical phenotype, average patient age at diagnosis and risk of metastases.

  • Genetic testing is an essential component of PHEO/PGL management, but can be costly and time‐consuming; newer techniques to resolve these limitations are being explored.

  • Messenger RNA expression profiles can help broadly classify PHEO/PGL into two well‐established clusters based on their broader mechanistic errors.

  • Additional clustering mechanisms are being proposed based on other analyses, including miRNA, transcriptomic, metabolomic and proteomic studies.

  • Beyond clustering, unifying theories to link PHEO/PGL susceptibility genes have been proposed to link all 17 genes to a common signalling pathway, focusing particularly on the processes of apoptosis and hypoxia response.

  • Identifying common targets between the genes could aid in the identification of novel treatment strategies for patients with these rare neuroendocrine tumours.

Keywords: genetics; pheochromocytoma; paraganglioma; hypoxia; hypoxia‐inducible factors; succinate dehydrogenase

Figure 1.

Recommended genetic testing algorithm for patients with PHEO/PGL. *If both normetanephrine and methoxytyramine are elevated, follow the algorithm for methoxytyramine. If both normetanephrine and metanephrine are elevated, follow the algorithm for metanephrine. **In patients with elevated normetanephrine with clinical features that do not clearly indicate which gene to test, perform immunohistochemistry for SDHB and SDHA. +If tumour is adrenal, TMEM127 testing may be considered. Abbreviations: DA, dopamine; HIF2A, hypoxia‐inducible factor 2‐alpha; HNP, head and neck PGL; h/o, history of; MAX, myc‐associated factor X; MEN2, multiple endocrine neoplasia type 2; MTY, methoxytyramine; NF1, neurofibromatosis type 1; RET, rearranged during transfection; SDHA, succinate dehydrogenase subunit A; SDHB, succinate dehydrogenase subunit B; SDHC, succinate dehydrogenase subunit C; SDHD, succinate dehydrogenase subunit D; TMEM127, transmembrane protein 127; VHL, von Hippel–Lindau. Adapted from Karasek et al. (). © US Government.

Figure 2.

Regulation of hypoxia‐inducible factors (HIFs) under normoxia and hypoxia. Multiple PHEO and PGL susceptibility genes are involved in HIF regulation, suggesting a common role for HIF in the pathogenesis of PHEO/PGL. Reproduced from Jochmanová et al. (). © US Government.

close

References

Baysal BE (2013) Mitochondrial complex II and genomic imprinting in inheritance of paraganglioma tumors. Biochimica et Biophysica Acta 1827(5): 573–577.

Buffet A, Smati S, Mansuy L et al. (2014) Mosaicism in HIF2A‐related polycythaemia‐paraganglioma syndrome. Journal of Clinical Endocrinology and Metabolism 99(2): E369–E373.

Burnichon N, Buffet A, Parfait B et al. (2012a) Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Human Molecular Genetics 21(26): 5397–5405.

Burnichon N, Cascón A, Schiavi F et al. (2012b) MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clinical Cancer Research 18(10): 2828–2837.

Burnichon N, Vescovo L, Amar L et al. (2011) Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Human Molecular Genetics 20(20): 3974–3985.

Castro‐Vega LJ, Buffet A, de Cubas AA et al. (2014) Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Human Molecular Genetics. [Epub ahead of print].

Comino‐Méndez I, de Cubas AA, Bernal C et al. (2013) Tumoral EPAS1 (HIF2A) mutations explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. Human Molecular Genetics 22(11): 2169–2176.

Comino‐Méndez I, Gracia‐Aznárez FJ, Schiavi F et al. (2011) Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nature Genetics 43(7): 663–667.

Crona J, Verdugo AD, Granberg D et al. (2013b) Next‐generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma. Endocrine Connections 2(2): 104–111.

Crona J, Verdugo AD, Maharjan R et al. (2013a) Somatic mutations in H‐RAS in sporadic pheochromocytoma and paraganglioma identified by exome sequencing. Journal of Clinical Endocrinology and Metabolism 98(7): E1266–E1271.

de Cubas AA, Leandro‐García LJ, Schiavi F et al. (2013) Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype‐specific markers and potentially regulated pathways. Endocrine‐Related Cancer 20(4): 477–493.

Dahia PLM, Ross KN, Wright ME et al. (2005) A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genetics 1(1): 72–80.

van Duinen N, Corssmit EPM, de Jong WHA et al. (2013) Plasma levels of free metanephrines and 3‐methoxytyramine indicate a higher number of biochemically active HNPGL than 24‐h urinary excretion rates of catecholamines and metabolites. European Journal of Endocrinology 169(3): 377–382.

Eisenhofer G, Huynh TT, Pacak K et al. (2004) Distinct gene expression profiles in norepinephrine‐ and epinephrine‐producing hereditary and sporadic pheochromocytomas: activation of hypoxia‐driven angiogenic pathways in von Hippel‐Lindau syndrome. Endocrine‐Related Cancer 11(4): 897–911.

Eisenhofer G, Lenders JWM, Timmers H et al. (2011) Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. Clinical Chemistry 57(3): 411–420.

Favier J, Brière JJ, Burnichon N et al. (2009) The Warburg effect is genetically determined in inherited pheochromocytomas. PloS One 4(9): e7094.

Gaal J, Burnichon N, Korpershoek E et al. (2010) Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. Journal of Clinical Endocrinology and Metabolism 95(3): 1274–1278.

Gimenez‐Roqueplo AP, Dahia PL and Robledo M (2012) An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Hormone and Metabolic Research 44(5): 328–333.

Huynh TT, Pacak K, Wong DL et al. (2006) Transcriptional regulation of phenylethanolamine N‐methyltransferase in pheochromocytomas from patients with von Hippel‐Lindau syndrome and multiple endocrine neoplasia type 2. Annals of the New York Academy of Sciences 1073: 241–252.

Jiang S and Dahia PLM (2011) Minireview: the busy road to pheochromocytomas and paragangliomas has a new member, TMEM127. Endocrinology 152(6): 2133–2140.

Jochmanová I, Yang C, Zhuang Z et al. (2013) Hypoxia‐inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. Journal of the National Cancer Institute 105(17): 1270–1283.

Karasek D, Shah U, Frysak Z, Stratakis C and Pacak K (2013) An update on the genetics of pheochromocytoma. Journal of Human Hypertension 27(3): 141–147.

Kim S, Kim DH, Jung WH and Koo JS (2013) Succinate dehydrogenase expression in breast cancer. SpringerPlus 2(1): 299.

Ladroue C, Carcenac R, Leporrier M et al. (2008) PHD2 mutation and congenital erythrocytosis with paraganglioma. New England Journal of Medicine 359(25): 2685–2692.

Lee S, Nakamura E, Yang H et al. (2005) Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8(2): 155–167.

Letouzé E, Martinelli C, Loriot C et al. (2013) SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 23(6): 739–752.

López‐Jiménez E, Gómez‐López G, Leandro‐García LJ et al. (2010) Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL‐related pheochromocytomas. Molecular Endocrinology 24(12): 2382–2391.

Lorenzo FR, Yang C, Ng Tang Fui M et al. (2013) A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. Journal of Molecular Medicine 91(4): 507–512.

McInerney‐Leo AM, Marshall MS, Gardiner B et al. (2014) Whole exome sequencing is an efficient and sensitive method for detection of germline mutations in patients with phaeochromocytomas and paragangliomas. Clinical Endocrinology 80(1): 25–33.

Pacak K, Jochmanova I, Prodanov T et al. (2013) New syndrome of paraganglioma and somatostatinoma associated with polycythemia. Journal of Clinical Oncology 31(13): 1690–1698.

Papathomas T, Gaal J, Corssmit EP et al. (2013). Non‐pheochromocytoma/paraganglioma tumors in patients with succinate dehydrogenase‐related pheochromocytomaparaganglioma syndromes: a clinicopathologic and molecular analysis. European Journal of Endocrinology 170(1): 1–12.

Pasini B, McWhinney SR, Bei T et al. (2008) Clinical and molecular genetics of patients with the Carney–Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. European Journal of Human Genetics 16(1): 79–88.

Patterson E, Webb R, Weisbrod A et al. (2012) The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma. Endocrine‐Related Cancer 19(2): 157–166.

Pollard PJ, El‐Bahrawy M, Poulsom R et al. (2006) Expression of HIF‐1alpha, HIF‐2alpha (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. Journal of Clinical Endocrinology and Metabolism 91(11): 4593–4598.

Qin Y, Yao L, King EE et al. (2010). Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nature Genetics 42(3): 229–233.

Rao JU, Engelke UFH, Rodenburg RJT et al. (2013) Genotype‐specific abnormalities in mitochondrial function associate with distinct profiles of energy metabolism and catecholamine content in pheochromocytoma and paraganglioma. Clinical Cancer Research 19(14): 3787–3795.

Rattenberry E, Vialard L, Yeung A et al. (2013) A comprehensive next generation sequencing‐based genetic testing strategy to improve diagnosis of inherited pheochromocytoma and paraganglioma. Journal of Clinical Endocrinology and Metabolism 98(7): E1248–E1256.

Ricketts C, Woodward ER, Killick P et al. (2008) Germline SDHB mutations and familial renal cell carcinoma. Journal of the National Cancer Institute 100(17): 1260–1262.

Schimke RN, Collins DL and Stolle CA (2010) Paraganglioma, neuroblastoma, and a SDHB mutation: resolution of a 30‐year‐old mystery. American journal of Medical Genetics 152A(6): 1531–1535.

Schlisio S, Kenchappa RS, Vredeveld LCW et al. (2008) The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes and Development 22(7): 884–893.

Semenza GL (2012) Hypoxia‐inducible factors in physiology and medicine. Cell 148(3): 399–408.

Shankavaram U, Fliedner SMJ, Elkahloun AG et al. (2013) Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas. Neoplasia 15(4): 435–447.

Taïeb D, Yang C, Delenne B et al. (2013) First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A‐related polycythemia–paraganglioma syndrome. Journal of Clinical Endocrinology and Metabolism 98(5): E908–E913.

Timmers HJLM, Pacak K, Huynh TT et al. (2008) Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. Journal of Clinical Endocrinology and Metabolism 93(12): 4826–4832.

Tömböl Z, Eder K, Kovács A et al. (2010) MicroRNA expression profiling in benign (sporadic and hereditary) and recurring adrenal pheochromocytomas. Modern Pathology 23(12): 1583–1595.

Wadt K, Choi J, Chung JY et al. (2012) A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma. Pigment Cell and Melanoma Research 25(6): 815–818.

Xekouki P and Stratakis CA (2012) Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? Endocrine‐Related Cancer 19(6): C33–C40.

Yang C, Matro JC, Huntoon KM et al. (2012) Missense mutations in the human SDHB gene increase protein degradation without altering intrinsic enzymatic function. FASEB Journal 26(11): 4506–4516.

Yang C, Sun MG, Matro J et al. (2013) Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood 121(13): 2563–2566.

Zhuang Z, Yang C, Lorenzo F et al. (2012) Somatic HIF2A gain‐of‐function mutations in paraganglioma with polycythemia. New England Journal of Medicine 367(10): 922–930.

Further Reading

Benn DE, Gimenez‐Roqueplo AP, Reilly JR et al. (2006) Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. Journal of Clinical Endocrinology and Metabolism 91(3): 827–836.

Boedeker CC, Hensen EF, Neumann HPH et al. (2014) Genetics of hereditary head and neck paragangliomas. Head and Neck. [Epub ahead of print].

Brouwers FM, Eisenhofer G, Tao JJ et al. (2006) High frequency of SDHB germline mutations in patients with malignant catecholamine‐producing paragangliomas: implications for genetic testing. Journal of Clinical Endocrinology and Metabolism 91(11): 4505–4509.

Dahia PL (2013) The genetic landscape of pheochromocytomas and paragangliomas: somatic mutations take center stage. Journal of Clinical Endocrinology and Metabolism 98(7): 2679–2681.

Eisenhofer G, Pacak K, Huynh TT et al. (2011) Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocrine‐Related Cancer 18(1): 97–111.

Fishbein L, Merrill S, Fraker DL, Cohen DL and Nathanson KL (2013) Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Annals of Surgical Oncology 20(5): 1444–1450.

Ni Y, Zbuk KM, Sadler T et al. (2008) Germline mutations and variants in the succinate dehydrogenase genes in Cowden and Cowden‐like syndromes. American Journal of Human Genetics 83(2): 261–268.

Vicha A, Musil Z and Pacak K (2013) Genetics of pheochromocytoma and paraganglioma syndromes: new advances and future treatment options. Current Opinion in Endocrinology & Diabetes and Obesity 20(3): 186–191.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Martucci, Victoria L, and Pacak, Karel(Apr 2014) Genetics of Pheochromocytoma. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0025302]